SARS-CoV-2 variants, immune escape, COVID-19 vaccine, and therapeutic strategies

doi:10.1007/s11427-021-2164-6

. 2023 Feb;66(2):406-410.

doi: 10.1007/s11427-021-2164-6. Epub 2022 Nov 3.

SARS-CoV-2 variants, immune escape, COVID-19 vaccine, and therapeutic strategies

Haiying Que^#¹, Li Chen^#¹, Xiawei Wei²

Affiliations

¹ Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, China.
² Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, China. xiaweiwei@scu.edu.cn.

^# Contributed equally.

PMID: 36342589
PMCID: PMC9638196
DOI: 10.1007/s11427-021-2164-6

SARS-CoV-2 variants, immune escape, COVID-19 vaccine, and therapeutic strategies

Haiying Que et al. Sci China Life Sci. 2023 Feb.

. 2023 Feb;66(2):406-410.

doi: 10.1007/s11427-021-2164-6. Epub 2022 Nov 3.

Authors

Haiying Que^#¹, Li Chen^#¹, Xiawei Wei²

Affiliations

¹ Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, China.
² Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, China. xiaweiwei@scu.edu.cn.

^# Contributed equally.

PMID: 36342589
PMCID: PMC9638196
DOI: 10.1007/s11427-021-2164-6

No abstract available

PubMed Disclaimer

Conflict of interest statement

Compliance and ethics The author(s) declare that they have no conflict of interest.

Cited by

Exploring immune evasion of SARS-CoV-2 variants using a pseudotyped system.
Duan H, Zhang E, Ren G, Cheng Y, Yang B, Liu L, Jolicoeur N, Hu H, Xu Y, Liu B. Duan H, et al. Heliyon. 2024 Apr 18;10(8):e29939. doi: 10.1016/j.heliyon.2024.e29939. eCollection 2024 Apr 30. Heliyon. 2024. PMID: 38699727 Free PMC article.
Immune rebalancing at the maternal-fetal interface of maternal SARS-CoV-2 infection during early pregnancy.
Xi C, Yan Z, Bai D, Zhang Y, Wang B, Han X, Wu L, Shi X, Hu Z, Tang M, Su Z, Liu Y, Liu B, Yin J, Wang H, Li X, Zhang Y, Gao S, Liu W. Xi C, et al. Protein Cell. 2024 May 28;15(6):460-473. doi: 10.1093/procel/pwae006. Protein Cell. 2024. PMID: 38441496 Free PMC article.
Elucidation of the neutralizing antibody evasion of emergent SARS-CoV-2 Omicron sub-lineages using structural analysis.
Sun C, Liu YT, Kang YF, Xie C, Li SX, Lu YT, Zeng MS. Sun C, et al. Sci China Life Sci. 2023 Dec;66(12):2935-2938. doi: 10.1007/s11427-023-2393-3. Epub 2023 Sep 1. Sci China Life Sci. 2023. PMID: 37673846 No abstract available.
A pan-coronavirus peptide inhibitor prevents SARS-CoV-2 infection in mice by intranasal delivery.
Wu L, Zheng A, Tang Y, Chai Y, Chen J, Cheng L, Hu Y, Qu J, Lei W, Liu WJ, Wu G, Zeng S, Yang H, Wang Q, Gao GF. Wu L, et al. Sci China Life Sci. 2023 Oct;66(10):2201-2213. doi: 10.1007/s11427-023-2410-5. Epub 2023 Aug 11. Sci China Life Sci. 2023. PMID: 37574525

References

1. Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657–663. doi: 10.1038/s41586-021-04385-3. - DOI - PMC - PubMed
1. Chen J, Wang R, Gilby NB, Wei GW. Omicron Variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62:412–422. doi: 10.1021/acs.jcim.1c01451. - DOI - PMC - PubMed
1. Gstöttner C, Zhang T, Resemann A, Ruben S, Pengelley S, Suckau D, Welsink T, Wuhrer M, Domínguez-Vega E. Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells. Anal Chem. 2021;93:6839–6847. doi: 10.1021/acs.analchem.1c00893. - DOI - PMC - PubMed
1. Jiang S, Zhang X, Du L. Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2. Expert Opin Ther Targets. 2021;25:415–421. doi: 10.1080/14728222.2020.1820482. - DOI - PMC - PubMed
1. Lazarevic I, Pravica V, Miljanovic D, Cupic M. Immune evasion of SARS-CoV-2 emerging variants: what have we learnt so far? Viruses. 2021;13:1192. doi: 10.3390/v13071192. - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657–663. doi: 10.1038/s41586-021-04385-3. - DOI - PMC - PubMed

[2] Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657–663. doi: 10.1038/s41586-021-04385-3. - DOI - PMC - PubMed

[3] Chen J, Wang R, Gilby NB, Wei GW. Omicron Variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62:412–422. doi: 10.1021/acs.jcim.1c01451. - DOI - PMC - PubMed

[4] Chen J, Wang R, Gilby NB, Wei GW. Omicron Variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62:412–422. doi: 10.1021/acs.jcim.1c01451. - DOI - PMC - PubMed

[5] Gstöttner C, Zhang T, Resemann A, Ruben S, Pengelley S, Suckau D, Welsink T, Wuhrer M, Domínguez-Vega E. Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells. Anal Chem. 2021;93:6839–6847. doi: 10.1021/acs.analchem.1c00893. - DOI - PMC - PubMed

[6] Gstöttner C, Zhang T, Resemann A, Ruben S, Pengelley S, Suckau D, Welsink T, Wuhrer M, Domínguez-Vega E. Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells. Anal Chem. 2021;93:6839–6847. doi: 10.1021/acs.analchem.1c00893. - DOI - PMC - PubMed

[7] Jiang S, Zhang X, Du L. Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2. Expert Opin Ther Targets. 2021;25:415–421. doi: 10.1080/14728222.2020.1820482. - DOI - PMC - PubMed

[8] Jiang S, Zhang X, Du L. Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2. Expert Opin Ther Targets. 2021;25:415–421. doi: 10.1080/14728222.2020.1820482. - DOI - PMC - PubMed

[9] Lazarevic I, Pravica V, Miljanovic D, Cupic M. Immune evasion of SARS-CoV-2 emerging variants: what have we learnt so far? Viruses. 2021;13:1192. doi: 10.3390/v13071192. - DOI - PMC - PubMed

[10] Lazarevic I, Pravica V, Miljanovic D, Cupic M. Immune evasion of SARS-CoV-2 emerging variants: what have we learnt so far? Viruses. 2021;13:1192. doi: 10.3390/v13071192. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

SARS-CoV-2 variants, immune escape, COVID-19 vaccine, and therapeutic strategies

Affiliations

SARS-CoV-2 variants, immune escape, COVID-19 vaccine, and therapeutic strategies

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous